FMS-like tyrosine kinase-3 (FLT3) is a new therapeutic target for acute myelocytic leukemia (AML), because FLT3 mutations are the most common genetic alterations in AML and are directly related to leukemogenesis. We studied cytotoxic interactions of a FLT3 inhibitor, PKC412, with eight conventional antileukemic agents (cytarabine, doxorubicin, idarubicin, mitoxantrone, etoposide, 4-hydroperoxy-cyclophosphamide, methotrexate and vincristine) using three leukemia cell lines carrying FLT3 mutations (MOLM13, MOLM14 and MV4-11) and five leukemia cell lines without FLT3 mutations (KOPB-26, THP-1, BALL-1, KG-1 and U937). PKC412 showed synergistic effects with all agents studied except methotrexate for FLT3-mutated cell lines in isobologram analysis. In contrast, PKC412 was rather antagonistic to most drugs, except for 4-hydroperoxy-cyclophosphamide and vincristine, in leukemia cell lines without FLT3 mutations. Cell-cycle analysis revealed that PKC412 induced G1 arrest in leukemia cell lines carrying FLT3 mutations, whereas it arrested cells in G2/M phase in the absence of FLT3 mutations, which may underlie the divergent cytotoxic interactions. These results suggest that the simultaneous administration of PKC412 and other agents except methotrexate is clinically effective against FLT3 mutationpositive leukemias, whereas it would be of little benefit for FLT3 mutation-negative leukemias. Our findings may be of help for the design of PKC412-based combination chemotherapy.
Introduction
Acute myelocytic leukemia (AML) is a clonal disease of hematopoietic progenitor cells characterized by failure of differentiation and uncontrolled proliferation. Although currently available therapies are able to induce complete remission in more than two-thirds of patients, the remission is often not durable and 70-80% of patients ultimately die of their disease. Therefore, novel therapeutic strategies are needed to improve prognosis. 1 Recent progress in molecular hematology has advanced our understanding of genetic changes that cause leukemic transformation. As great success has been demonstrated in the use of all-trans retinoic acid for acute promyelocytic leukemia 2 and imatinib mesylate for Philadelphia chromosome-positive leukemias, 3 targeting signal transducers for leukemic stem cells has become a major strategy for researchers to seek more effective and less toxic treatments.
The FMS-like tyrosine kinase-3 (FLT3) is a member of class III receptor tyrosine kinases, and structurally related to c-KIT, c-FMS and platelet-derived growth factor-receptor (PDGF-R) tyrosine kinases. 4, 5 FLT3 is expressed in early hematopoietic stem cells, and plays an important role in the survival and expansion of multipotent progenitor cells. 5 The binding of FLT3 ligand induces dimerization and autophosphorylation of the receptor and subsequent activation of downstream signaling pathways, favoring cell survival and proliferation. 6 FLT3 is also expressed in the majority of acute leukemias. 7 Moreover, mutations of FLT3 are found in approximately 30% of patients with AML and accordingly are the most common genetic alterations in AML. 7, 8 They are also found in a small number of patients with acute lymphocytic leukemia and myelodysplastic syndromes. 7, 8 FLT3 mutations involve either internal tandem duplication (ITD) of the juxtamembrane (JM) domain (FLT3-ITD) and/or point mutations in the activating loop, [7] [8] [9] which appear to constitutively activate the receptor in a ligand-independent manner, promoting proliferation and survival of leukemia cells. In fact, FLT3-ITD mutations induce myeloproliferative disease in a murine bone marrow transplant model. 10 Several clinical studies have indicated that AML carrying FLT3-ITD is associated with worse prognosis. 9, [11] [12] [13] Because of the high frequency of mutations, FLT3 is a novel therapeutic target in AML.
14 Selective FLT3 inhibitors have the potential to suppress aberrant FLT3 signaling. 14, 15 The staurosporine derivative PKC412 has been shown to inhibit multitarget tyrosine kinases, including FLT3. 16 PKC412 induces apoptosis in blasts from AML patients with FLT3 mutations, and prolongs survival in animal models of FLT3-induced myeloproliferative diseases. 10, 16 To date, several FLT3 inhibitors (PKC412, MLN518, SU11248, SU5416 and CEP-701) have been developed for clinical trials. 17 Although PKC412 has been evaluated in the treatment of patients with AML and various solid tumors, PKC412 alone has yielded limited clinical activity. 18, 19 Other FLT3 inhibitors showed similar limited efficacy in clinical trials. [20] [21] [22] [23] [24] The common strategy for solving this problem is to combine PKC412 with other antileukemic agents. However, to our knowledge, no data have been reported for the cytotoxic interactions of PKC412 with other agents. We therefore studied the cytotoxic effects of PKC412 in combination with conventional antileukemic agents using human leukemia cell lines. We found that the combination of PKC412 and other antileukemic agents produced strikingly different effects on leukemic cells depending on the presence of FLT3 mutations. This finding may be important for the design of PKC412-based combination chemotherapy.
Materials and methods

Cell lines
Experiments were conducted using eight human leukemia cell lines: MOLM13 and MOLM14 from a patient with acute monocytic leukemia (M5a) carrying t(9;11), 25 MV4-11 from a patient with AML carrying t(4;11), 26 KOPB-26 from a patient with AML carrying t(9;11), 27 THP-1 from a patient with acute monocytic leukemia (M5) carrying t(9;11) 28 and BALL-1, KG-1 and U937 from patients with B-cell acute lymphoblastic leukemia, AML and acute monocytic leukemia, respectively. MV4-11 and THP-1 were purchased from American Type Culture Collection (Manassas, VA, USA). KOPB-26 was kindly provided by Dr Kanji Sugita (University of Yamanashi, Yamanashi, Japan). BALL-1, KG-1 and U937 were obtained from Health Science Research Resources Bank (Osaka, Japan).
The doubling times of all cell lines were 20-30 h under our experimental conditions. Cells were maintained in 75-cm 2 plastic tissue culture flasks containing RPMI1640 medium (Sigma Chemical Co., St Louis, MO, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Grand Island Biological Co., Grand Island, New York, NY, USA) and antibiotics (penicillin G and streptomycin) in a humidified atmosphere of 95% air/5% CO 2 at 371C.
Detection of FLT3 mutations
Polymerase chain reaction with reverse transcription (RT-PCR) and direct DNA sequencing were used for the detection of FLT3 mutations. Total RNA was extracted from cell lines by using ISOGEN reagent (Nippon Gene, Toyama, Japan). First-strand cDNA was synthesized from 1 mg of RNA with SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and random hexamers. Mutations in the JM domain of FLT3 were identified by amplifying a segment spanning exons 14 and 15 with primers FLT3.1675F (5 00 -GACAACATCTCATTCTATGCA AC-3 00 ) and FLT3.18R1 (5 00 -TCTGAACTTCTCTTGAACCA-3 00 ). Activation loop mutations in exon 20 were analyzed by using primers FLT3.2263F (5 00 -AGCATGCCTGGTTCAAGAGAAGT-3 00 ) and FLT3.2728R (5 00 -TTAGCATCAACCGGAATGCC-3 00 ). The thermal cycling profile was: 941C for 2 min, followed by 40 cycles of 941C for 30 s, 551C for 30 s, 721C for 1 min and a final extension at 721C for 5 min. PCR products were separated by electrophoresis on a 1.5% agarose gel, cut out from the gel, purified with a QIAquick gel extraction kit (Qiagen, Chatsworth, CA, USA) and directly sequenced with an ABI PRISM 310 (PE Applied Biosystems, Foster City, CA, USA).
Antileukemic agents
PKC412 was kindly provided by Novartis Pharma AG (Basel, Switzerland). Other antileukemic agents used and their sources are: cytarabine (Nihon Shinyaku Co. Ltd, Tokyo, Japan), doxorubicin (Meiji Co. Ltd, Tokyo), idarubicin and mitoxantrone (Weiss Lederle Japan Ltd, Tokyo, Japan), methotrexate (Weiss Lederle Japan Ltd), etoposide (Nihon Kayaku), 4-hydroperoxycyclophosphamide (an active form of cyclophosphamide) and vincristine (Shionogi Co. Ltd, Tokyo, Japan). All drugs were dissolved in RPMI1640 medium except that PKC412 was dissolved in dimethyl sulfoxide. The stock solutions were prepared at 1 mM or 100 mM and stored at À801C. Appropriate drug concentrations were made by dilution with fresh medium immediately before experiments. The final concentration of dimethyl sulfoxide in the culture medium was o0.1%, a concentration that did not affect the drug effects in the present study.
Cell culture
Logarithmically growing leukemia cells were harvested and resuspended at a final concentration of 2 Â 10 5 cells/ml in fresh medium for MOLM13, MOLM14 and MV4-11 cells, and 1 Â 10 5 cells/ml for KOPB-26, THP-1, BALL-1, KG-1 and U937 cells. The cell suspension (100 ml) was dispensed into individual wells of a 96-well tissue culture plate with a lid (Falcon, Oxnard, CA, USA). Eight plates were prepared for the testing of each drug combination. Each plate had one eight-well blank columncontaining medium alone and one eight-well control column containing cells but no drugs. Solutions (50 ml) of PKC412 and other drugs at various concentrations were added simultaneously to eight wells containing cell suspensions. Cells were continuously exposed to the drugs for 4 days.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay
After incubation for 4 days, viable cell growth was determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) reduction assay as described previously. 29 For the blank, control (no drug), single drugs and combination, the four intermediate data values among the eight data values were used for the analysis after the two highest and two lowest values were discarded. For all cell lines examined, we established a linear relation between the MTT assay value and the cell number within the range of the experiments shown.
The isobologram of Steel and Peckham
The cytotoxic interactions of PKC412 with other agents at the point of IC 80 were evaluated using the isobologram of Steel and Peckham. 30 The IC 80 was defined as the concentration of drug that produced 80% cell growth inhibition, that is 80% reduction of absorbance. The theoretical bases of the isobologram method and the procedure for making isobolograms have previously been described in detail. 31, 32 On the basis of the dose-response curves of PKC412 and the other agents, three isoeffect curves were constructed (Figure 1) . If the agents act additively by independent mechanisms, combined data points would lie near the mode I line (heteroaddition). If the agents act additively by similar mechanisms, combined data points would lie near the mode II line (isoaddition). As it is not known in advance whether the combined effects of two agents would be hetero-additive, iso-additive or an effect intermediate between these extremes, all possibilities should be considered. Thus, when the data points of the drug combination fell within the area surrounded by three lines (envelope of additivity), the combination was regarded as additive. When the data points fell to the left of the envelope, that is the combined effect was caused by lower doses of the two agents than was predicted, the drug combination was regarded as supra-additive (synergism). When the points fell to the right of the envelope, that is the combined effect was caused by higher doses of the two agents than was predicted, but within the square or on the line of the square, the combination was regarded as subadditive, that is the combination was superior or equal to a single agent but caused less than an additive effect. When the data points were outside the square, the combination was regarded as protective, that is the combination was inferior in cytotoxic action to a single agent. Both subadditivity and protection were considered antagonism.
Data analysis
When the observed data points in the combinations mainly fell in the area of supra-additivity or in the areas of subadditivity and protection, that is the mean value of the observed data was smaller than that of the predicted minimum values or larger than that of the predicted maximum values, the combinations were considered to have a synergistic or antagonistic effect, respectively. The Wilcoxon signed-rank test was used to compare the observed data with the predicted minimum (or maximum) values for additive effects, which were closest to the observed data (i.e. the data on the boundary (mode I or mode II lines) between the additive area and supra-additive area (or subadditive and protective areas)). 33 Combinations with significant values (Po0.05) were defined as having a synergistic effect (or an antagonistic effect), and those with insignificant values (P40.05) were defined as having an additive/synergistic effect (or an additive/antagonistic effect). All statistical analyses were performed using the StatView 4.01 software program (Abacus Concepts, Berkeley, CA, USA).
Results
FLT3 mutations detected in leukemia cell lines used in this study
In MOLM13 and MOLM14 cells, which are two sister cell lines, two mutations within FLT3 exon 14 were found ( Figure 2a) ; a duplication of 21 bp corresponding to codons Phe594-Asp600 Figure 1 Schematic representation of an isobologram (Steel and Peckham) . The concentrations that produced 80% cell growth inhibition are expressed as 1.0 on the ordinate and the abscissa of isobolograms. The envelope of additivity, surrounded by mode I (solid line) and mode II (broken lines) isobologram lines, is constructed from the dose-response curves of PKC412 and a combined drug. When the data points of the drug combination fall within the area surrounded by the envelope of additivity (Pb), the combination is regarded as additive. When the data points fall to the left of the envelope (Pa), the drug combination is regarded as supra-additive (synergism). When the points fall to the right of the envelope but within the square or on the square line (Pc), the combination is regarded as subadditive. When the data points are outside the square (Pd), the combination is regarded as protective. We consider both subadditive and protective interactions to be antagonistic effects. Cytotoxic interaction between PKC412 and other antileukemic agents
We analyzed the cytotoxic interaction between PKC412 and other agents by using the isobologram method of Steel and Peckham as described in the Materials and methods section. To make isobolograms, we first obtained the dose-response curves for PKC412 combined with other agents. As an example, Figure 4 shows the dose-response curves of PKC412 in combination with doxorubicin for MOLM13, KOPB-26 and KG-1 cells. We generated the individual isobolograms based on these curves to analyze the effects of each drug combination.
Cytotoxic effects of PKC412 in combination with cytarabine
The upper row of Figure 5a shows the isobolograms of this combination in MOLM13, KOPB-26 and KG-1 cells. In MOLM13 cells, all but one data points in the combination fell in the area of supra-additivity. The mean value of the data (0.60) was significantly smaller than that of the predicted minimum values (0.66; Po0.02 by the Wilcoxon signed-rank test), indicating a synergistic effect of the simultaneous exposure to PKC412 and cytarabine (Table 2) . Synergistic effects were also observed in MOLM14 and MV4-11 cells (Table 2, (Table 2) . Finally, in KOPB-26 cells, all data points fell within the envelope of additivity, suggesting an additive effect (Figure 5a ).
Cytotoxic effects of PKC412 in combination with doxorubicin
The lower row of Figure 5a shows the isobolograms of this combination in MOLM13, KOPB-26 and KG-1 cells. In MOLM13 cells, all but one data points in the combination fell in the area of supra-additivity. The observed value was significantly smaller than the predicted minimum value (Po0.05), indicating synergistic effects of the simultaneous exposure to PKC412 and doxorubicin (Table 2 ). MOLM14 and MV4-11 showed quite similar responses. In KOPB-26 and BALL-1 cells, all data points fell within the envelope of additivity, suggesting additive effects of this combination, whereas all data points fell in the area of protection in THP-1, KG-1 and U937 cells, indicating an antagonistic effect ( Table 2 ). 
Cytotoxic effects of PKC412 in combination with idarubicin
In MOLM13 and MV4-11 cells, all data points fell in the area of supra-additivity, indicating a synergistic effect of this combination (Table 2 , isobolograms not shown). In MOLM14, KOPB-26 and THP-1 cells, all data points fell within the envelope of additivity, indicating an additive effect. In contrast, an antagonistic effect was observed in BALL-1, KG-1 and U939 cells.
Cytotoxic effects of PKC412 in combination with mitoxantrone
In MOLM13, MOLM14 and MV4-11 cells, data points fell in the area of supra-additivity and within the envelope of additivity.
The mean values of the data were not significantly smaller than those of the predicted minimum values (P40.05), indicating additive/synergistic effects of this combination ( Table 2 , isobolograms not shown). In KOPB-26, THP-1 and BALL-1 cells, all data points fell within the envelope of additivity, indicating an additive effect. In contrast, all or most data points fell in the areas of subadditivity and protection, suggesting antagonistic effects in KG-1 and U937 cells.
Cytotoxic effects of PKC412 in combination with etoposide
In MOLM13, MOLM14 and MV4-11 cells, all data points fell in the area of supra-additivity, indicating synergistic effects of this combination ( Table 2 , isobolograms not shown). In KOPB-26 cells, all data points fell within the envelope of additivity, suggesting an additive effect. In THP-1 cells, data points fell within the envelope of additivity and in the area of subadditivity, which is regarded as additive/antagonism. In BALL-1, KG-1 and U937 cells, all or most data points fell in the areas of subadditivity and protection, suggesting antagonistic effects.
Cytotoxic effects of PKC412 in combination with 4-hydroperoxy-cyclophosphamide
As some patients with acute lymphocytic leukemia were FLT3 mutation-positive, 7 we also studied the combination of PKC412 with 4-hydroperoxy-cyclophosphamide, methotrexate and vincristine. In MOLM13, MOLM14 and MV4-11 cells, all data points fell in the area of supra-additivity, indicating a synergistic effect of this combination ( Table 2 , isobolograms not shown). In all other cell lines examined, all or most data points fell within the envelope of additivity, suggesting additive effects. No antagonistic effect was observed with the combination of PKC412 and 4-hydroperoxy-cyclophosphamide in any cell lines tested.
Cytotoxic effects of PKC412 in combination with methotrexate
The upper row of Figure 5b shows the isobolograms of this combination in MOLM13, KOPB-26 and KG-1 cells. In MOLM13 cells, all but two data points fell in the area of protection. Although the mean value of the data (0.80) was larger than that of the predicted maximal values (0.68), the difference was not statistically significant (P40.05) ( Table 2) , which suggests additive/antagonistic affects. In KOPB-26 and KG-1 cells, all or most data points fell within the areas of subadditivity and protection (Figure 5b ). The observed data were significantly larger than the predicted maximal values, indicating an antagonistic effect of the simultaneous exposure to PKC412 and methotrexate (Table 2) . Antagonistic effects were also observed in the other cell lines examined (Table 2) .
Cytotoxic effects of PKC412 in combination with vincristine
The lower row of Figure 5b shows the isobolograms of this combination in MOLM13, KOPB-26 and KG-1 cells. In MOLM13, MOLM14 and KG-1 cells, all data points fell in the area of supra-additivity, indicating synergistic effects of this (Table 2 ). In KOPB-26 and THP-1 cells, all data points fell in the area of supra-additivity and within the envelope of additivity, indicating additive/synergistic effects. No antagonistic effect was observed with the combination of PKC412 and vincristine in any cell lines tested.
Cell-cycle analysis of leukemia cells treated with PKC412 in combination with other agents
The isobologram analysis revealed that PKC412 had a synergistic effect with most antileukemic agents for leukemic cell lines carrying FLT3 mutations, whereas it showed a synergistic effect only with vincristine in leukemic cell lines without FLT3 mutations. We attempted to clarify the underlying mechanisms of this observation using cell-cycle analysis. To this end, we performed cell-cycle analysis of MOLM13, MV4-11 and U937 cells treated with PKC412 in combination with cytarabine, doxorubicin and vincristine. Both cytarabine and doxorubicin arrested cells in late G1 to early S phase in these cell lines, whereas vincristine caused mitotic arrest (Supplementary Figure 1) . When applied as single agents, these drugs induced apoptosis in 10-20% of total cells. In MOLM13 and MV4-11 PKC412 in combination with other antileukemic agents Y Furukawa et al Table 2 Mean values of observed data and predicted minimum and maximum values of PKC412 in combination with other anticancer agents 
Discussion
Clinical studies of FLT3 inhibitors have been performed in advanced AML cases, but have shown limited clinical activity of these agents. [17] [18] [19] [20] [21] [22] [23] [24] Therefore, the combination of FLT3 inhibitors with conventional antileukemic agents may be a better strategy to improve treatment outcome for AML patients. Here, we studied the cytotoxic interactions between one of the FLT3 inhibitors, PKC412, and eight conventional antileukemic agents using various leukemia cell lines. FLT3 mutations were detected in three (MOLM13, MOLM14 and MV4-11) out of eight cell lines used in this study. A Tyr599Phe point mutation and sevencodon duplication within FLT3 exon 14 were detected in MOLM13 and MOLM14 cells, and a 30-bp duplication within FLT3 exon 14 in MV4-11 cells. The Tyr599Phe point mutation is a novel one, which has not been previously reported among cell lines nor patients with FLT3 mutations. 34, 35 Interestingly, the Tyr599Phe and seven-codon duplication were found in the same allele. An ITD of 30 bp found in MV4-11 cells resulted in an additional histidine in the middle of the duplication.
Although PKC412 had cytotoxic effects against all leukemia cell lines tested, FLT3 mutation-carrying cell lines (MOLM13, MOLM14 and MV4-11) were much more sensitive to PKC412 than FLT3 mutation-negative cell lines (KOPB-26, THP-1, BALL-1, KG-1 and U937). The IC 80 levels against FLT3 mutation-negative cell lines are about 10 times higher than those against leukemic cell lines carrying FLT3 mutations. The sensitivity is not related to the presence of MLL gene rearrangements, which are observed in MOLM13, MOLM14, MV4-11, KOPB-26 and THP-1 cells among the cell lines used in this study. 27, 28, 36 The concentration of PKC412 that inhibits the autophosphorylation of FLT3 to 50% of the baseline level has been reported to be approximately 10 nM, 16, 37 suggesting that PKC412 inhibits the growth of MOLM13, MOLM14 and MV4-11 solely by FLT3 inhibitory activity. The concentration of PKC412 required to induce substantial levels of cell death for FLT3 mutation-negative cell lines is much higher than the concentration needed to completely inhibit FLT3 phosphorylation. Therefore, it is plausible that PKC412 targets other tyrosine kinases, such as protein kinase C, KDR, c-KIT and PDGF-R, to exert cytotoxicity against FLT3 mutation-negative cells. 16, 17 In the present study, we observed that PKC412 produced divergent cytotoxic effects in FLT3 mutation-positive versus -negative leukemia cell lines, when combined with major anti-AML agents such as cytarabine, doxorubicin, idarubicin, mitoxantrone and etoposide (see Table 3 for summary). Namely, PKC412 produced mainly synergistic effects with these agents against leukemia cell lines carrying FLT3 mutations, whereas it had a tendency to produce antagonistic effects against cell lines without FLT3 mutations. Similar combined effects were observed at the IC 50 levels (data not shown). The synergistic effects are not owing to the modulation of P-glycoprotein expression by the drug (Supplementary Figure 2) . These data suggest that the simultaneous administration of PKC412 and anti-AML agents would be very effective and recommended for FLT3 mutationpositive AML in clinical settings. On the other hand, the same combination in FLT3 mutation-negative leukemias would presumably be of little benefit when provided simultaneously, but a different schedule might improve therapeutic outcome.
We also studied the combination of PKC412 with antileukemic agents commonly used for acute lymphoblastic leukemia such as 4-hydroperoxy-cyclophosphamide, vincristine and methotrexate (see Table 3 for summary). For these combinations, no obvious divergent effects were observed between FLT3 mutation-positive and -negative leukemia cell lines. In combination with 4-hydroperoxy-cyclophosphamide, PKC412 had synergistic effects against FLT3 mutation-positive cell lines and additive effects against FLT3 mutations-negative cell lines. In combination with vincristine, PKC412 showed favorable effects regardless of the status of FLT3. Finally, the combination of PKC412 with methotrexate was antagonistic in all leukemia cell lines studied, as other drugs did with methotrexate. 29, 31, 32 In isobologram analysis, when the data points fell to the left of the envelope, the drug combination is regarded as synergism. Lower ratios of the observed data/the predicted minimum values mean that the combinations are more synergistic. 33 The observed data of PKC412 in combination with cytarabine, doxorubicin, idarubicin, etoposide, 4-hydroperoxy-cyclophosphamide and vincristine are 70-100% of the predicted minimum values in most of FLT-3 mutation-positive cell lines (Table 2 ). There is no obvious difference in the ratios of the observed data/the predicted minimum values between the combinations. We therefore recommend cytarabine and/or topoisomerase-II inhibitors for clinical use with PKC412 in AML, because cyclophosphamide and vincristine are not so active against AML. On the other hand, the combination of PKC412 with topoisomerase-II inhibitors, cyclophosphamide or vincristine would be recommended for FLT3 mutation-positive acute lymphoblastic leukemia.
To confirm the results obtained with PKC412, we carried out the same experiments with another FLT3 inhibitor, SU5614 (obtained from Takara Bio, Osaka, Japan). FLT3 mutationpositive cells were more than 10 times more sensitive to SU5614 than FLT3 mutation-negative cells. In MOLM13 cells, SU5614 produced quite similar combined effects with other agents as PKC412 (data not shown).
We had a chance to perform combination studies using two clinical AML samples. As more than 1 Â 10 8 cells were required for each combination in our experimental system, only hyperleukocytic leukemia samples (495% blast) could be used. As primary leukemic cells were more resistant to antileukemic agents than leukemia cell lines studied, we evaluated the combined effects at the IC 50 levels. Both cases were FLT3 mutation-negative, and the IC 50 against PKC412 were 1850 and 1000 nM, respectively. In one case, PKC412 produced antagonistic effects with idarubicin, doxorubicin and etoposide, and in the other case, PKC412 showed additive effects with idarubicin and mitoxantrone, and antagonistic effects with doxorubicin (data not shown). Primary AML cells did not grow in vitro but rather decreased during cell culture even without drug exposure, whereas leukemia cell lines grew rapidly during drug exposure. Considering the different cell kinetics, the findings with clinical samples are consistent with the experimental data from leukemia cell lines. Although we could not fully confirm the results obtained with cell lines, some clinical trials involving the combination of PKC412 and conventional antileukemic agents are ongoing (for example, see Stone et al. 19 ). Our study would be a nice reference to the evaluation of the clinical studies.
There have been a few reports regarding the combination of FLT3 inhibitors and conventional antileukemic agents. Levis et al. 38 reported the effects of CEP-701 in combination with daunorubicin, etoposide, cytarabine and mitoxantrone on several FLT3 mutation-carrying cells. They found that simultaneous exposure and sequential exposure with CEP-701 added after chemotherapeutic agents produced synergistic effects, whereas the reverse-sequence exposure resulted in an antagonistic effect. Yee et al. 39 reported that SU11248 had synergistic effects with daunorubicin and cytarabine in several leukemic cell lines carrying FLT3 mutations. A similar tendency was observed in our study, although the FLT3 inhibitors used were different in each study.
In conclusion, PKC412 showed a synergistic effect with cytarabine, doxorubicin, idarubicin, mitoxantrone, etoposide, 4-hydroperoxy-cyclophosphamide and vincristine for FLT3-mutated cell lines. In contrast, PKC412 was rather antagonistic to most drugs, except for 4-hydroperoxy-cyclophosphamide and vincristine, in leukemia cell lines without FLT3 mutations. These results suggest that the simultaneous administration of PKC412 and other agents except methotrexate is clinically effective against FLT3 mutation-positive leukemias, whereas it would be of little benefit for FLT3 mutation-negative leukemias. Although there are a number of difficulties in the translation of the results of in vitro studies to the bedside, our findings may be of help for the design of PKC412-based combination chemotherapy.
